European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Optimal treatment for patients with solid tumours in Europe through Artificial intelligence

Descripción del proyecto

Mejora del tratamiento de los pacientes con cáncer de próstata, mama y pulmón

Se prevé que el número de casos nuevos de cáncer en Europa aumente un 14 % para 2030. Esto provoca una demanda creciente de tratamientos innovadores contra el cáncer entre los pacientes. En este contexto, en el proyecto OPTIMA, financiado con fondos europeos, se reunirá a la Sociedad Respiratoria Europea y la Fundación Europea del Pulmón, junto con otros treinta y cuatro socios. El objetivo es diseñar, desarrollar y suministrar la primera plataforma europea interoperable de generación de pruebas y datos oncológicos reales, junto con conjuntos de herramientas de apoyo a la toma de decisiones para el cáncer de próstata, pulmón y mama. Los investigadores del proyecto OPTIMA establecerán procedimientos de mejores prácticas para la integración de los análisis y las pruebas basados en herramientas y tecnología de inteligencia artificial (IA).

Objetivo

OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individualised treatments and to innovative therapies. In that perspective, we will design, develop and deliver the first interoperable and GDPR compliant European real-world oncology data and evidence generation platform, along with decision support toolsets for prostate, lung and breast cancer. By designing this platform from the onset based on the needs of the clinicians and patients in an inclusive and sustainable way, OPTIMA aims to strengthen shared decision-making based on innovative data and AI-driven technology and tools.

To achieve our vision, we have united the key partners from other data-driven European wide oncology initiatives (PIONEER, EHDEN, HARMONY) in our project along with Europes leading clinicians in the fields of breast, prostate and lung cancer that all have leading roles in medical societies such as ERS, ESMO, and EAU. At the core of the OPTIMA project are the major guideline offices of the three indications, whilst the project is further strengthened by patient advocacy groups, well-known academic partners and 6 SMEs as partners covering the needed expertise to implement OPTIMA successfully.

The platform will build on existing open source solutions such as the OMOP-CDM, tranSMART and OHDSI ATLAS whilst developing novel AI models based on federated learning to facilitate knowledge discovery. At the start of the project, we will already have access to datasets covering over 200M people in Europe, along with data from high quality patient cohorts for AI model building. Moreover, the platform will be hosted in-kind on existing infrastructure provided by Helmholtz Institute in Germany. Finally, OPTIMA envisions sustainability of its platform through a value-based approach with various business models for commercial users.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

STICHTING EUROPEAN UROLOGICAL FOUNDATION
Aportación neta de la UEn
€ 822 280,00
Dirección
Mr. E.N. van Kleffenstraat 5
6842 CV Arnhem
Países Bajos

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Oost-Nederland Gelderland Arnhem/Nijmegen
Tipo de actividad
Other
Enlaces
Coste total
€ 2 800 280,00

Participantes (39)